Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice

Table 1

Characteristics of patients diagnosed with glioblastoma.

Characteristic	n (%)
Age at diagnosis (years)
18-39	15 (4.9)
40-49	29 (9.4)
50-59	58 (18.9)
60-69	85 (27.7)
70-79	75 (24.4)
≥ 80	45 (14.7)
Year of diagnosis
1995-1999	89 (29.0)
2000-2004	74 (24.1)
2005-2009	89 (29.0)
2010-2012	55 (17.9)
Male	181 (59.0)
Race
White	295 (96.0)
African-American	1 (0.3)
Asian	2 (0.7)
American Indian or Alaska native	2 (0.7)
Unknown	7 (2.3)
Charlson comorbidity score
0	155 (50.5)
1	29 (9.5)
2	60 (19.5)
≥ 3	63 (20.5)
Presenting symptoms
Headaches	160 (52.1)
Seizures	75 (24.4)
Nausea/vomiting	48 (15.6)
Sensory deficit^1	56 (18.2)
Motor deficit^2	137 (44.6)
Confusion/memory loss	175 (57.0)
Extent of surgery
Resection	180 (58.6)
Biopsy	113 (36.8)
Unknown	14 (4.6)
Radiation dose
60 Gy	147 (47.9)
< 60 Gy	47 (15.3)
Unknown dose	24 (7.8)
No radiotherapy	89 (29.0)
Chemotherapy
Temozolomide only	44 (14.3)
Temozolomide and other agents	86 (28.0)
Non-temozolomide agents only	46 (15.0)
No chemotherapy	131 (42.7)
Tumor location - supratentorial
Frontal	124 (40.4)
Parietal	105 (34.2)
Temporal	136 (44.3)
Occipital	43 (14.0)
Corpus callosum	42 (13.7)
Thalamus	13 (4.2)
Tumor location - infratentorial
Cerebellum	11 (3.6)
Brainstem	6 (2.0)
Tumor location - unknown	4 (1.3)

A sensory deficit was defined as decreased sensation to any stimulus. A motor deficit was defined as decreased strength and/or difficulty with movement or coordination.